tbuckley/cabot-search huggingface dataset:
Core implementation strategies for improving cirrhosis care in the Veterans Health Administration
Authors: Vera Yakovchenko, Timothy R. Morgan, Edward J. Miech, Brittney Neely, Carolyn Lamorte, Sandra Gibson, Lauren A. Beste, Heather McCurdy, Dawn Scott, Rachel I. Gonzalez, Angela M. Park, Byron J. Powell, Jasmohan S. Bajaj, Jason A. Dominitz, Maggie Chartier, David B. Ross, Matthew J. Chinman, Shari S. Rogal
Journal: Hepatology (2022)

Abstract Background and Aims The Veterans Health Administration (VHA) provides care for more than 80,000 veterans with cirrhosis. This longitudinal, multimethod evaluation of a cirrhosis care quality improvement program aimed to (1) identify implementation strategies associated with evidence‐based, guideline‐concordant cirrhosis care over time, and (2) use qualitative interviews to operationalize strategies for a manualized intervention. Approach and Results VHA providers were surveyed annually about the use of 73 implementation strategies to improve cirrhosis care in fiscal years 2018 (FY18) and 2019 (FY19). Implementation strategies linked to guideline‐concordant cirrhosis care were identified using bivariate statistics and comparative configurational methods. Semistructured interviews were conducted with 12 facilities in the highest quartile of cirrhosis care to specify the successful implementation strategies and their mechanisms of change. A total of 106 VHA facilities (82%) responded at least once over the 2‐year period (FY18, n = 63; FY19, n = 100). Facilities reported using a median of 12 (interquartile range [IQR] 20) implementation strategies in FY18 and 10 (IQR 19) in FY19. Of the 73 strategies, 35 (48%) were positively correlated with provision of evidence‐based cirrhosis care. Configurational analysis identified multiple strategy pathways directly linked to more guideline‐concordant cirrhosis care. Across both methods, a subset of eight strategies was determined to be core to cirrhosis care improvement and specified using qualitative interviews. Conclusions In a national cirrhosis care improvement initiative, a multimethod approach identified a core subset of successful implementation strategy combinations. This process of empirically identifying and specifying implementation strategies may be applicable to other implementation challenges in hepatology.
Covid-19: Past infection may not protect against future variants, researcher warns
Authors: Elisabeth Mahase
Journal: BMJ (2022)

Past infection with covid-19 does not necessarily confer protection against future infection, especially when it comes to the delta and omicron variants, researchers have warned.Wendy Barclay, head of infectious disease at Imperial College London, told an event organised by the Zoe study group 1 on 3 February, "Each variant is different from the starting virus, but it's not necessarily a linear difference.If you can picture in three dimensional space the original Wuhan one sitting in the middle-some of the other variants have sort of gone out from Wuhan but in different directions.The two that are most different from each other are delta and omicron."She said people who think their past infection will give them good protection against future variants may be mistaken, and that this is a powerful reason to get vaccinated."You're actually better off being vaccinated, even if you get infected on top of that vaccine, as we can see that it broadens out the immune response and gives you potentially better protection against all the other variants that are going to come a little later," Barclay said. 1 The Omicron variant: what does it mean for the future of covid?https://covid.joinzoe.com/webinar/omicron-variant-dominant.2
Disparities in the conduct of oral food challenges between Black and White children in the FORWARD cohort
Authors: Annika Chura, Amal Assa'ad, Lili Ding, Lucy Bilaver, Khalid Ibrahim, Christopher Warren, Neil Thivalapill, Aame Andy Nweye, Susan Fox, Mahboobeh Mahdavinia, Mary Tobin, Amaziah Coleman, Linda Herbert, Izeris Ortiz Rodriguez, Hemant Sharma, Ososese Enaholo, Haley Hultquist, Jialing Jiang, Davida Kay, Pamela Newmark, Sai Nimmagada, Jacqueline Pongracic, Stephanie Shigo, Eileen Vincent, Mark Wlodarski, Andrea Pappalardo, Ruchi Gupta, Jennifer Long
Journal: Journal of Allergy and Clinical Immunology (2022)
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Authors: Len Neckers, Paul Workman
Journal: Clinical Cancer Research (2012)

Abstract Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-associated kinases and transcription factors, and it is essential for oncogenic transformation. Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clinical trials. Investigators established Hsp90′s druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity. Preclinical data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clinical activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer. Many optimized synthetic, small-molecule Hsp90 inhibitors from diverse chemotypes are now in clinical trials. Here, we review the discovery and development of Hsp90 inhibitors and assess their potential. There has been significant learning from studies of the basic biology of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chemical probes. Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (especially multiple myeloma) in which buffering of proteotoxic stress is critical for survival. We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70. Clin Cancer Res; 18(1); 64–76. ©2012 AACR.
Incidental Detection of Mandibular Metastasis in Renal Cell Carcinoma on 99mTc-MIBI Scan
Authors: Rachita Rungta, Melvika Pereira, Natasha Singh, Divya Shivdasani, Jugal Kesariya, Debdip Roy, Shreya Dang
Journal: Clinical Nuclear Medicine (2022)

Abstract MIBI scintigraphy is the most widely used modality to identify parathyroid adenomas preoperatively. However, MIBI is also known to accumulate in multiple benign and malignant lesions. In renal cell carcinoma, 30% of the patients present with distant metastasis, commonly lungs and bone; however, jaw bone metastases are extremely rare (&lt;1% of oral malignancies). Here we present a rare case of MIBI-avid mandibular metastasis in bilateral renal cell carcinoma on 99m Tc-MIBI scintigraphy. Thus, we emphasize on careful interpretation of 99m Tc-MIBI scans, which in addition to parathyroid adenomas can incidentally detect concurrent malignant lesions.
Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma
Authors: Mohamed H. Shamji, Hanisah Sharif, Janice A. Layhadi, Rongfei Zhu, Uday Kishore, Harald Renz
Journal: Journal of Allergy and Clinical Immunology (2022)

Allergen immunotherapy (AIT) is an effective treatment for allergic rhinitis, inducing long-term clinical tolerance to the sensitizing allergen. Clinical tolerance induction can be achieved when AIT is administered for at least 3 years. AIT is associated with the modulation of innate and adaptive immune systems. This comprises inhibition of IgE-dependent activation of mast cells and basophils in the local target organ, suppression of TH2 cells, immune deviation toward TH1 cells, induction of T and B regulatory cells, and production of allergen-neutralizing antibodies. However, recent developments in their underpinning mechanisms have revealed that AIT, administered subcutaneously or sublingually, induces immune regulation through novel cell targets and molecular mechanisms. This comprehensive review discusses how immune tolerance driven by subcutaneous immunotherapy and sublingual immunotherapy is associated with the induction of a novel regulatory subset of innate lymphoid cells and suppression of proinflammatory TH2, allergen-specific TH2 (TH2A), and T follicular helper cells. Moreover, they are associated with exhaustion of TH2A cells and differential expression of nasal and systemic IgA antibodies. Uncovering the underpinning mechanisms of a successful AIT and immune tolerance induction will allow the development of targeted therapeutics for allergic rhinitis with and without asthma.
IODOFORM DERMATITIS.
Authors: W. A. BRYAN
Journal: JAMA (1903)

It is the purpose of this paper to notice a phase of action iodoform sometimes assumes in the form of a dermatitis. By the term local iodoform dermatitis I have meant to distinguish this process from that showing constitutional involvement and an eruption scattered more or less over the body. This general involvement is well understood, but the purely local condition has been but little written of, and is probably not generally recognized as being produced by the application of iodoform, even when it does appear. My reason for calling this local iodoform dermatitis is the fact that it comes only on the surface surrounding the wound to which iodoform has been applied, produces no eruption or discomfort elsewhere and shows no special constitutional symptoms. <h3>THE CLINICAL COURSE.</h3> The appearance of the surface begins to change toward the end of the first 24 to 48 hours after application
Involutional Melancholia
Authors: J GIBSON
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
American tests of medical competence.
Journal: BMJ (1978)

peace of mind.Such a policy must not, however, be adopted in prepubertal girls.Anxious parents commonly bring a girl aged between 8 and 12 to a breast clinic with a 1-2 cm discoid mass beneath one nipple.The mass is due to asymmetrical development of the breast disc of early puberty.Surgical interference in such a case is a catastrophe: removal of the breast disc at this stage will inevitably mean complete failure of development of the breast on that side.
使用阿那白滞素对治疗掌跖脓疱病没有益处
Journal: British Journal of Dermatology (2022)

Journal Article 使用阿那白滞素对治疗掌跖脓疱病没有益处 Get access British Journal of Dermatology, Volume 186, Issue 2, 1 February 2022, Page e106, https://doi.org/10.1111/bjd.20934 Published: 01 February 2022
Allergen provocation tests in respiratory research: building on 50 years of experience
Authors: Gail M. Gauvreau, Beth E. Davis, Guy Scadding, Louis-Philippe Boulet, Leif Bjermer, Adam Chaker, Donald W. Cockcroft, Barbro Dahlén, Wyste Fokkens, Peter Hellings, Nikolaos Lazarinis, Paul M. O'Byrne, Ellen Tufvesson, Santiago Quirce, Maurits Van Maaren, Frans H. de Jongh, Zuzana Diamant
Journal: European Respiratory Journal (2022)

The allergen provocation test is an established model of allergic airway diseases, including asthma and allergic rhinitis, allowing the study of allergen-induced changes in respiratory physiology and inflammatory mechanisms in sensitised individuals as well as their associations. In the upper airways, allergen challenge is focused on the clinical and pathophysiological sequelae of the early allergic response, and is applied both as a diagnostic tool and in research settings. In contrast, bronchial allergen challenge has almost exclusively served as a research tool in specialised research settings with a focus on the late asthmatic response and the underlying type 2 inflammation. The allergen-induced late asthmatic response is also characterised by prolonged airway narrowing, increased nonspecific airway hyperresponsiveness and features of airway remodelling including the small airways, and hence allows the study of several key mechanisms and features of asthma. In line with these characteristics, allergen challenge has served as a valued tool to study the cross-talk of the upper and lower airways and in proof-of-mechanism studies of drug development. In recent years, several new insights into respiratory phenotypes and endotypes including the involvement of the upper and small airways, innovative biomarker sampling methods and detection techniques, refined lung function testing as well as targeted treatment options further shaped the applicability of the allergen provocation test in precision medicine. These topics, along with descriptions of subject populations and safety, in line with the updated Global Initiative for Asthma 2021 document, will be addressed in this review.
Implementing a Hospital-Wide Inpatient Beta-Lactam Allergy Guideline Leads to Consistent Increases in Beta-Lactam Use
Authors: Iris Otani, Monica Tang, Karen Anstey, Lusha Wang, Alexandra Hilts-Horeczko, Fanny Li, Vincent Le, Melissa Lee, Jennifer Mulliken, Rachel Bystritsky, Sarah Doernberg
Journal: Journal of Allergy and Clinical Immunology (2022)
Graphene-based nanomaterials for cancer therapy and anti-infections
Authors: Yan Wang, Juan Li, Xiaobin Li, Jinping Shi, Zhaotan Jiang, Can Yang Zhang
Journal: Bioactive Materials (2022)

Graphene-based nanomaterials (GBNMs) has been thoroughly investigated and extensively used in many biomedical fields, especially cancer therapy and bacteria-induced infectious diseases treatment, which have attracted more and more attentions due to the improved therapeutic efficacy and reduced reverse effect. GBNMs, as classic two-dimensional (2D) nanomaterials, have unique structure and excellent physicochemical properties, exhibiting tremendous potential in cancer therapy and bacteria-induced infectious diseases treatment. In this review, we first introduced the recent advances in development of GBNMs and GBNMs-based treatment strategies for cancer, including photothermal therapy (PTT), photodynamic therapy (PDT) and multiple combination therapies. Then, we surveyed the research progress of applications of GBNMs in anti-infection such as antimicrobial resistance, wound healing and removal of biofilm. The mechanism of GBNMs was also expounded. Finally, we concluded and discussed the advantages, challenges/limitations and perspective about the development of GBNMs and GBNMs-based therapies. Collectively, we think that GBNMs could be potential in clinic to promote the improvement of cancer therapy and infections treatment.
Klatte K, Chaitman BR, Theroux P, Gavard JA, Stocke K, Boyce S, Bartels C, Keller B, Jessel A, for the GUARDIAN Investigators. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial
Journal: Journal of the American College of Cardiology (2002)
THE UNHEALTHFUL LONG SKIRT.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer
Authors: James A. Fagin
Journal: Journal of Clinical Oncology (2022)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers. January 11, 2022 ARTICLE CITATION DOI: 10.1200/JCO.21.02864 Journal of Clinical Oncology - published online before print February 1, 2022 PMID: 35104153 Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer James A. Fagin , MD1xJames A. FaginSearch for articles by this author Show More 1Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY https://doi.org/10.1200/JCO.21.02864 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTSupported in part by NIH-RO1-CA249663 (J.A.F.) and NIH-P30-CA08748 (Craig Thompson).AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTAge of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).James A. FaginHonoraria: Eisai EuropeConsulting or Advisory Role: Loxo OncologyPatents, Royalties, Other Intellectual Property: MSK Ref. SK 2014-024-03 Title: Treatment of H-RAS–Driven Tumors. Application Number: 15/305,788, Anti-TSHR Multispecific Antibodies and Uses Thereof. Provisional patent (Inst)No other potential conflicts of interest were reported. Companion Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers
S105: ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI CONDITIONING IMPROVES DONOR CHIMERISM IN MATCHED SIBLING DONOR STEM CELL TRANSPLANTATION IN ADULT SICKLE CELL DISEASE PATIENTS
Authors: E Dovern, M Aydin, M Tang, L Suijk, C van Tuijn, S Zeerleder, M Hazenberg, B Biemond, E Nur
Journal: HemaSphere (2022)

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only established curative treatment option for sickle cell disease (SCD). In adults, myeloablative conditioning is associated with significant toxicity, primarily due to cumulative organ damage. Matched sibling donor (MSD) transplantation with non-myeloablative conditioning (alemtuzumab/3 Gy total body irradiation (TBI)) has shown promising results in adult SCD patients.1,2 Patients treated with this regimen had their sickle cell phenotype corrected with only mild complications and no reports of graft-versus-host disease (GvHD). However, most of the described patients did not reach complete donor chimerism with graft failure rates of 13%. Furthermore, in almost 10% of patients, immunosuppressives could not be withdrawn because of too low T cell chimerism (<50%).2 We hypothesized that adding azathioprine and hydroxyurea as preconditioning to the alemtuzumab/TBI regimen might improve donor chimerism, reduce the risk of graft failure and improve successful withdrawal of immunosuppressives. Aims: In this study we prospectively investigate the effects of azathioprine/hydroxyurea preconditioning on donor chimerism and graft failure in patients receiving non-myeloablative MSD HSCT for SCD. Methods: Adult SCD patients who had an HLA-identical sibling donor were eligible for this treatment. After 3 months of azathioprine 150mg qd and hydroxyurea 25mg/kg qd, erythrocyte exchange transfusion was performed on day –10, aiming for HbS <30%. Conditioning with alemtuzumab/TBI was started on day –7. Graft versus host disease (GvHD) prophylaxis consisted of sirolimus. Results: As of October 2021, 13 SCD patients (median age 30.6 (range 19–49) years) were transplanted. Twelve patients (92.3%) engrafted successfully. After a median follow-up of 24 months, median donor myeloid and T cell chimerism of engrafted patients were 100% (IQR 84–100%) and 77% (IQR 70.5%-82.5%), respectively. These donor chimerism percentages are higher than previously reported with alemtuzumab/TBI only. All engrafted patients had a corrected SCD phenotype with normalized hemoglobin levels. Patients reaching 1-year post-transplantation were able to stop sirolimus without decreases in chimerism. Summary/Conclusion: Azathioprine/hydroxyurea preconditioning prior to alemtuzumab/TBI results in improved donor chimerism, potentially reducing the risk of graft failure after non-myeloablatieve MSD transplantation in SCD patients. Importantly, all engrafted patients reached donor T cell chimerism >50% at 1-year post-transplantation and were able to stop immunosuppressives as scheduled. References 1. Hsieh et al, NEJM 2009; 361:24 2. Alzahrani et al, BJH 2021; 192:4